Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 7/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.34 |
| ▸ | ALDH1A2 | O94788 | 6/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872062 | 0.84 | PDE11A (0.44) | MAT2AGRM1ALDH1A1ALDH1A2ALDH1A3 | |
| SCHEMBL8287044 | 0.80 | PIM1 (0.31) | — | |
| SCHEMBL8286382 | 0.79 | PDE11A (0.44) | MAT2AALDH1A1HPGDPIK3CDMEN1 | |
| SCHEMBL8285126 | 0.74 | PDE11A (0.36) | GRM1ALDH1A1ALDH1A2ALDH1A3KDM4E | |
| SCHEMBL8285115 | 0.74 | BPTF (0.36) | ALDH1A1KDM4EHPGDTP53MAPT | |
| SCHEMBL8287801 | 0.73 | ALDH1A2 (0.37) | ALDH1A1ALDH1A2ALDH1A3KDM4EMAPT | |
| SCHEMBL8285132 | 0.73 | APP (0.40) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL5872009 | 0.72 | PDE11A (0.44) | MAT2AALDH1A1ALDH1A2ALDH1A3KDM4E | |
| SCHEMBL8285172 | 0.72 | PDE11A (0.40) | MAT2AALDH1A1ALDH1A2ALDH1A3HPGD | |
| SCHEMBL8285121 | 0.71 | ALDH1A1 (0.39) | MAT2AALDH1A1ALDH1A3KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109196-B2 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-24 | — | — | US | disclosed |
| US-6964971-B2 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-15 | — | — | US | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| US-6900205-B2 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1432710-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1432711-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6677352-B1 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-01-13 | — | — | US | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027113-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, NQO1, UQCRC1 | MAT2A 4508/4885GRM1 4289/4885ALDH1A1 850/4885 |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | SLC5A1, NQO1, GLP1R | MAT2A 4368/4885GRM1 4343/4885ALDH1A1 754/4885 |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | UQCRC1, GLP1R, SLC5A1 | MAT2A 4368/4885GRM1 4324/4885ALDH1A1 820/4885 |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, UQCRC1, SLC5A1 | MAT2A 4338/4885GRM1 4491/4885ALDH1A1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.